Gefitinib clinical trials
Also written Iressa and ZD1839.
How each study uses Gefitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Gefitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 5 May 2003 · IRESSA · NDA 021399 (FDA, Drugs@FDA)
- European Union
- 24 Jun 2009 · Iressa · EMEA/H/C/001016 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
228 studies that test it; most in 2004 (42)
| Year | Studies |
|---|---|
| 2000 | 2 |
| 2001 | 17 |
| 2002 | 22 |
| 2003 | 38 |
| 2004 | 42 |
| 2005 | 22 |
| 2006 | 8 |
| 2007 | 5 |
| 2008 | 5 |
| 2009 | 9 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 9 |
| 2013 | 5 |
| 2014 | 8 |
| 2015 | 6 |
| 2016 | 6 |
| 2017 | 4 |
| 2018 | 5 |
| 2020 | 4 |
| 2024 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 61 · Other 170
AstraZeneca (49) · National Cancer Institute (NCI) (22) · M.D. Anderson Cancer Center (5) · European Organisation for Research and Treatment of Cancer - EORTC (5) · University of Chicago (4) · Fudan University (4) · Samsung Medical Center (4) · Memorial Sloan Kettering Cancer Center (4)
Often tested with
Tested in the same studies.
Cisplatin (15) · Docetaxel (9) · Pemetrexed (8) · Carboplatin (5) · Erlotinib (5) · Gemcitabine (5) · Fluorouracil (5) · Paclitaxel (4)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Gefitinib is the comparator. A study of two new drugs counts under both.
- 1ASK-120067 · Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- 1Aflutinib · Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Reaching primary completion within a year · 1
Studies that test Gefitinib.
- Nov 2026Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver CancerPhase 2 · First Affiliated Hospital of Wenzhou Medical University
Studies
Open first, then newest update. How each study uses Gefitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 231
- Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver CancerNot yet recruitingPhase 2First Affiliated Hospital of Wenzhou Medical UniversityNCT07829926Written as GefitinibHow we know
- A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07477457Written as GefitinibHow we know
- Therapy for Advanced NSCLC With EGFR 19delins MutationNot yet recruitingEarly Phase 1Fuzhou General HospitalNCT07458919Written as Icotinib/GefitinibHow we know
- Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsRecruitingPhase 1/2China Medical University HospitalNCT06071013Written as Nintedanib, gefitinib, erlotinib, afatinib, osimertinibHow we know
- Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFRNot yet recruitingNot applicableQilu Pharmaceutical Co., Ltd.NCT03381430Written as GefitinibHow we know
- Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC PatientsNot yet recruitingPhase 3Sun Yat-sen UniversityNCT03203590Written as GefitinibHow we know
- Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerActive, not recruitingPhase 1/2Dana-Farber Cancer InstituteNCT03122717Written as GefitinibHow we know
- A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung CancerCompletedPhase 1/2Stanford UniversityNCT00238628Written as IressaHow we know
- Bioequivalence Study of Gefitinib Tablets Under Fasting ConditionsCompletedPhase 1Hunan Kelun Pharmaceutical Co., Ltd.NCT03050164Written as Gefitinib Tablet 250mg of Hunan KelunHow we know
- Bioequivalence Study of Gefitinib Tablets Under Fed ConditionsCompletedPhase 1Hunan Kelun Pharmaceutical Co., Ltd.NCT03050177Written as Gefitinib Tablet 250mg of Hunan KelunHow we know
- ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung CancerCompletedPhase 1Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT00328562Written as ZD1839 (Iressa)How we know
- Treatment of Lung Adenocarcinoma With Bronchioloalveolar FeatureCompletedPhase 2Intergroupe Francophone de Cancerologie ThoraciqueNCT00198380Written as GefitinibHow we know
- A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell CarcinomaCompletedPhase 2University of ChicagoNCT01185158Written as ZD1839 (IRESSA)How we know
- Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line ChemotherapyCompletedPhase 2Seoul Veterans HospitalNCT01485809Written as GefitinibHow we know
- Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone TherapyTerminatedPhase 2University of NebraskaNCT00483561Written as Gefitinib plus etoposideHow we know
- BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder CancerTerminatedPhase 3NCIC Clinical Trials GroupNCT00352079Written as gefitinibHow we know
- Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular CarcinomaCompletedNot applicableRenJi HospitalNCT04642547Written as Lenvatinib and GefitinibHow we know
- Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)CompletedPhase 2Fudan UniversityNCT01833572Written as GefitinibHow we know
- Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck CancerCompletedPhase 2University of ChicagoNCT01185171Written as ZD 1839 500mgHow we know
- Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)CompletedPhase 1/2Merck KGaA, Darmstadt, GermanyNCT01982955Written as GefitinibHow we know
See all 231 studies that test Gefitinib →
Given beside what is tested · 44 — Gefitinib is usual care or a partner of the new treatment
- Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCActive, not recruitingPhase 1Novartis PharmaceuticalsNCT03333343Written as gefitinibHow we know
- A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)Active, not recruitingPhase 3Eli Lilly and CompanyNCT02411448Written as GefitinibHow we know
- Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment AloneActive, not recruitingPhase 2Novartis PharmaceuticalsNCT03040973Written as GefitinibHow we know
- Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)CompletedPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT02856893Written as GefitinibHow we know
- Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M NegativeCompletedPhase 1/2Sunshine Lake Pharma Co., Ltd.NCT03758287Written as GefitinibHow we know
- A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung CancerTerminatedPhase 2Massachusetts General HospitalNCT03292133Written as GefitinibHow we know
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruitingPhase 2AstraZenecaNCT03944772Written as GefitinibHow we know
- Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib AloneCompletedPhase 1/2Spanish Lung Cancer GroupNCT01513174Written as GefitinibHow we know
- A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFRCompletedPhase 1National Cancer Centre, SingaporeNCT01570296Written as Gefitinib and BKM120How we know
- DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerTerminatedPhase 1Daiichi Sankyo Co., Ltd.NCT03599518Written as GefitinibHow we know
- A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT02039674Written as GefitinibHow we know
- MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).CompletedPhase 1MedImmune LLCNCT02088112Written as GefitinibHow we know
- Efficacy and Safety of Precision Therapy in Refractory TumorStatus unknownPhase 2Baodong QinNCT03239015Written as GefitinibHow we know
- A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi TreatmentCompletedPhase 2Novartis PharmaceuticalsNCT01610336Written as GefitinibHow we know
- A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung CancerCompletedPhase 2Hutchison Medipharma LimitedNCT02976116Written as GefitinibHow we know
- Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLCStatus unknownPhase 3Sun Yat-sen UniversityNCT04028778Written as GefitinibHow we know
- A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 2Eli Lilly and CompanyNCT01469000Written as GefitinibHow we know
- Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary AdenocarcinomaCompletedPhase 3Shanghai University of Traditional Chinese MedicineNCT02889692Written as Gefitinib®How we know
- Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary AdenocarcinomaStatus unknownPhase 3Shanghai University of Traditional Chinese MedicineNCT02929693Written as gefitinibHow we know
- Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung CancerStatus unknownNot applicableThe First Affiliated Hospital of Soochow UniversityNCT03766490Written as GefitinibHow we know
Showing 20 of 44.
As the comparator · 18 — what is tested is compared with Gefitinib
- Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)CompletedPhase 3Yuhan CorporationNCT04248829Written as Gefitinib 250 mgHow we know
- AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerCompletedPhase 3AstraZenecaNCT02296125Written as Gefitinib 250 mgHow we know
- First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) MetastasesCompletedPhase 2/3Alpha Biopharma (Jiangsu) Co., Ltd.NCT03653546Written as GefitinibHow we know
- Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAG)Active, not recruitingPhase 3Allist Pharmaceuticals, Inc.NCT03787992Written as Gefitinib 250 mgHow we know
- A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating MutationsTerminatedPhase 3Astellas Pharma Global Development, Inc.NCT02588261Written as GefitinibHow we know
- A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer PatientsStatus unknownPhase 3Beta Pharma ShanghaiNCT03866499Written as GefitinibHow we know
- ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLCActive, not recruitingPhase 3Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT04143607Written as GefitinibHow we know
- ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.CompletedPhase 3PfizerNCT01774721Written as GefitinibHow we know
- A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in PatientsStatus unknownPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT03849768Written as GefitinibHow we know
- LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the LungCompletedPhase 2Boehringer IngelheimNCT01466660Written as gefitinibHow we know
- A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerStatus unknownPhase 3Nanjing Sanhome Pharmaceutical, Co., Ltd.NCT04239833Written as GefitinibHow we know
- Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR MutationStatus unknownPhase 3Hangzhou ACEA Pharmaceutical Research Co., Ltd.NCT03856697Written as Gefitinib TabletsHow we know
- the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)Status unknownPhase 4Jiangsu Famous Medical Technology Co., Ltd.NCT03264794Written as Gefitinib tablets (Yi Ruisha),First medicationHow we know
- Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 MutationsCompletedPhase 3Chinese Society of Lung CancerNCT01024413Written as gefitinibHow we know
- A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung CancerCompletedPhase 1/2AVEO Pharmaceuticals, Inc.NCT01039948Written as AV-299 + gefitinibHow we know
- Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung CancerCompletedPhase 2Yonsei UniversityNCT01498562Written as Gefitinib and NimotuzumabHow we know
- Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) PatientsCompletedPhase 3Betta Pharmaceuticals Co., Ltd.NCT01040780Written as GefitinibHow we know
- CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung CancerTerminatedPhase 2Kunming Medical UniversityNCT01871480Written as Group A:cytokine-induced killer cell +gefitinibHow we know
Codes
What other systems call Gefitinib · ClinicalTrials.gg INT006655
- MeSH (NLM) D000077156GefitinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) S65743JHBSGEFITINIBConfirmed FDA, NLM, Wikidata
- RxNorm 328134Confirmed FDA, Wikidata
- Wikidata Q417824gefitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1855GefitinibOne source FDA
- DrugBank DB00317One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077156 | Gefitinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | S65743JHBS | GEFITINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 328134 | — | Confirmed FDA, Wikidata |
| Wikidata | Q417824 | gefitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1855 | Gefitinib | One source FDA |
| DrugBank | DB00317 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.